ABSTRACT
Importance There is a paucity of data that can be used to guide the management of critically ill patients with coronavirus disease 2019 (COVID-19). Global collaboration offers the best chance of obtaining these data, at scale and in time. In the absence of effective therapies, insights derived from real-time observational data will be a crucial means of improving outcomes.
Objective In response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, a research and data-sharing collaborative has been assembled to harness the cumulative experience of intensive care units (ICUs) worldwide. The resulting observational study provides a platform to rapidly disseminate detailed data and insights.
Design The COVID-19 Critical Care Consortium observational study is an international, multicenter, prospective, observational study of patients with confirmed or suspected SARSCoV-2 infection admitted to ICUs.
Setting This is an evolving, open-ended study that commenced on January 1st, 2020 and currently includes more than 350 sites in over 48 countries. The study enrolls patients at the time of ICU admission and follows them to the time of death, hospital discharge, or 28 days post-ICU admission, whichever occurs last.
Participants All subjects, without age limit, requiring admission to an ICU for SARS-CoV-2 infection, confirmed by real-time polymerase chain reaction (PCR) and/or next-generation sequencing or with high clinical suspicion of the infection. Patients admitted to an ICU for any other reason are excluded.
Main outcomes and measures Key data, collected via an electronic case report form devised in collaboration with the ISARIC/SPRINT-SARI networks, include: patient demographic data and risk factors, clinical features, severity of illness and respiratory failure, need for non-invasive and/or mechanical ventilation and/or extracorporeal membrane COVID–19 CCC observational study protocol oxygenation (ECMO), and associated complications, as well as data on adjunctive therapies. Final outcomes of in-hospital death, discharge or continuing admissions at 28 days.
Discussion This large-scale, observational study of COVID-19 in the critically ill will provide rapid international characterization. Open-ended accrual will increase the power to answer hypothesis-led questions over time. Several sub-studies have already been initiated, examining hemostasis, neurological, cardiac, and long-term outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ACTRN12620000421932
Funding Statement
The Common Good, an initiative of The Prince Charles Hospital Foundation, Brisbane, Queensland, Australian; Wesley Medical Research, UnitingCare Health, Australia
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research and Ethics Committee, Alfred Health, Melbourne, Australia Project Number: 62066 (Local Reference: Project 108/20) Project Title: ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (ECMOCARD)Coordinating Principal Investigator: Professor John Fraser was considered under the National Mutual Acceptance (NMA) scheme by the Ethics Committee on 27-Feb-2020, meets the requirements of the National Statement on Ethical Conduct in Human Research (2007) and was APPROVED on 2-Mar-2020.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The coordinating team will have access to all collected data to assure integrity, provide oversight, and conduct the main study analyses. Individual sites will have access to all the data they collect. A multinational steering committee [Supplement 1] oversees registry operations worldwide and approves investigator-initiated or site-specific sub-studies, external requests for data, and reviews suggestions by participants. To date, several sub-studies have been initiated focusing on the impact of COVID-19 on the brain, heart, kidneys, management and risks of ECMO, coagulation and thrombosis risks and long-term effects, all involving multi-center participation. Once approval is obtained, relevant de-identified data will be made available. It is anticipated that, following study completion, all de-identified data will be made open access.
